Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy
Strong NPM-139 safety and tolerability profile: -0 of 10 NPM-139 subjects experienced adverse events
Strong NPM-139 safety and tolerability profile: -0 of 10 NPM-139 subjects experienced adverse events